Two Sigma Advisers
HRTX icon

Two Sigma Advisers’s Heron Therapeutics HRTX Stock Holding History

Two Sigma Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-519,571
Closed -$675K – 982
2025
Q4 		$675K Buy
519,571
+337,500
+185% +$417K ﹤0.01% 1670
2025
Q3 		$229K Sell
182,071
-351,700
-66% -$558K ﹤0.01% 2087
2025
Q2 		$1.1M Sell
533,771
-135,400
-20% -$277K ﹤0.01% 1390
2025
Q1 		$1.47M Sell
669,171
-154,700
-19% -$300K ﹤0.01% 1282
2024
Q4 		$1.26M Buy
823,871
+12,500
+2% +$20.3K ﹤0.01% 1354
2024
Q3 		$1.61M Buy
811,371
+697,871
+615% +$1.67M ﹤0.01% 1185
2024
Q2 		$397K Buy
113,500
+71,400
+170% +$219K ﹤0.01% 1971
2024
Q1 		$117K Buy
42,100
+3,100
+8% +$7.79K ﹤0.01% 2288
2023
Q4 		$66.3K Sell
39,000
-4,500
-10% -$4.96K ﹤0.01% 2373
2023
Q3 		$44.8K Sell
43,500
-18,000
-29% -$25.6K ﹤0.01% 2285
2023
Q2 		$71.3K Sell
61,500
-1,400
-2% -$2.5K ﹤0.01% 2242
2023
Q1 		$95K Sell
62,900
-17,900
-22% -$44.8K ﹤0.01% 2390
2022
Q4 		$202K Buy
80,800
+54,100
+203% +$174K ﹤0.01% 2187
2022
Q3 		$113K Buy
+26,700
New +$104K ﹤0.01% 2293
2020
Q1 		– Sell
-14,100
Closed -$331K – 2506
2019
Q4 		$331K Buy
+14,100
New +$312K ﹤0.01% 2033

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Two Sigma Advisers's HRTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 519,571 shares — an estimated $675K sold.

Two Sigma Advisers first reported a position in HRTX in Q4 2019 and held it in 15 quarters. The position peaked at $1.61M in Q3 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 519,571 Heron Therapeutics shares in Q1 2026, an estimated $675K.
  • Two Sigma Advisers first reported a position in Heron Therapeutics in Q4 2019 and held it in 15 quarters.
  • Two Sigma Advisers's Heron Therapeutics position peaked at $1.61M in Q3 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.